- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Right Turn Show- Exploring Dapagliflozin Beyond Glycemic Benefits - Video
Overview
In the last episode, we explored the role of Dapagliflozin in specialty care settings. Moving forward, this episode delves into Dapagliflozin Beyond Glycemic Benefits. We are excited to bring you Episode 3 of the Right Turn Show, featuring two eminent experts in their respective fields: Dr Jamshed J. Dalal – Interventional Cardiologist & Honorary Director of Cardiac Sciences, Kokilaben Dhirubhai Ambani Hospital, Mumbai. Dr Pramila Kalra is a Renowned Endocrinologist, Professor, & Head of Endocrinology, Ramaiah Medical College & Hospital, Bangalore.
Dapagliflozin is widely used for managing Type 2 Diabetes and has proven benefits in treating heart failure and chronic kidney disease (CKD).
In this episode, Dr Dalal and Dr Kalra will discuss its expanded role beyond glycemic control, covering:
- Long-Term Benefits and First-Line Use of Dapagliflozin in Indian T2DM Care
- Clinical Benefits of Dapagliflozin on Intermediate Cardiovascular Risk Markers in Primary Prevention
- Initiating Dapagliflozin-Sitagliptin Dual and Triple FDC in Uncontrolled T2DM: Timing and Benefits
- Recent Cardiovascular Endpoint Benefits of Dapagliflozin in T2DM
- Nephroprotective and Clinical Endpoint Benefits of Dapagliflozin in T2DM with CKD
- Recent Cardiovascular Endpoint Benefits of Dapagliflozin in Heart Failure